Le Lézard
Classified in: Health
Subject: WOM

Belly Bandit® Introduces the Luxetm Belly WrapWhen a Belly Wrap Meets a Corset - You're in Luxe!


LOS ANGELES, Sept. 17, 2019 /PRNewswire-PRWeb/ -- The Luxetm Belly Wrap's patented-design blends the best features of the company's wraps and corsets to create an incredible, form-fitting wrap that provides the ultimate in targeted postpartum compression and support. The Luxetm boasts an innovative design and Belly Bandit's® exclusive Stayputtm technology.

Luxetm Belly Wrap ($99.95)

"The Luxetm was a decade in the making, and as you'll see, worth the wait," said Jodi Caden, Designer and Co-founder, Belly Bandit®. "We listened to our customers and created a wrap that provides maximum support, while thin and lightweight, so it can be worn comfortably and discreetly under clothes."

Belly Bandit's® proprietary SecureStretchtm fabric applies targeted compression, which may help:

Compress and support the belly, waist and hips

The Luxetm Belly Wrap is eligible for insurance reimbursement in the U.S. and on sale now at bellybandit.com.

Belly Bandit® is a for women by women company, dedicated to its mission of empowering women to look and feel their absolute best before, during and after pregnancy. The company has evolved from its signature product, the Belly Bandit®, Belly Wrap and expanded to include, maternity wear, intimates, and a complete line of compression shapewear.

 

SOURCE Belly Bandit


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: